title: [Diagnostics and new treatment methods of syndrome of inappropriate antidiuretic hormone secretion (SIADH)].
abstract: New treatment methods of syndrome of inappropriate antidiuretic hormone secretion (SIADH) has emerged with the oral vasopressin V2-receptor antagonist (VV2RA) tolvaptan, but its therapeutic window remains to be defined. We present the scientific data and describe treatment possibilities of SIADH while raising the questions: "Does the present evidence enable us to identify who to treat with VV2RAs?" and "is VV2RAs justified as first-line treatment?".
authors.affiliation: Medicinsk Endokrinologisk Afdeling, Aarhus Universitetshospital, Nørrebrogade, Denmark. chrtro@rm.dk
authors.forename: Christian
authors.initials: C
authors.lastname: Trolle
authors.forename: Søren
authors.initials: S
authors.lastname: Rittig
authors.forename: Jørgen
authors.initials: J
authors.lastname: Frøkjær
authors.forename: Jens Otto Lunde
authors.initials: JO
authors.lastname: Jørgensen
mesh_terms: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D006801:Humans; D007177:Inappropriate ADH Syndrome / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D011379:Prognosis; D012965:Sodium Chloride / Q000627:therapeutic use; D000077602:Tolvaptan; D014508:Urea / Q000627:therapeutic use; D014882:Water-Electrolyte Balance
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D000077602:Tolvaptan; D012965:Sodium Chloride; D014508:Urea